E. Kunder

Serum deoxyribonuclease activity and anti-nuclear antibodies in ankylosing spondilitis during longterm infliximab therapy

D. Petrovich, E. Kunder, 2018, Immunopathology, Allergology, Infectology.

DNA-hydrolysing activity of IgG antibodies from the sera of patients with diseases caused by different bacterial infections

E. Odintsova, V. Buneva, G. Nevinsky, 2008, Journal of cellular and molecular medicine.

Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults.

V. Mazurov, E. Nasonov, I. Gordeev, 2019, Clinical and experimental rheumatology.

OP0028 Efficacy and safety of bcd-085, a novel il-17 inhibitor, in ankylosing spondylitis. results of phase 2 clinical study

V. Mazurov, T. Dubinina, S. Erdes, 2018, WEDNESDAY, 13 JUNE 2018.

Efficacy and safety of netakimab, anti-IL-17A monoclonal antibody, in patients with ankylosing spondylitis. Results of phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA

V. Mazurov, S. Lapshina, I. Gordeev, 2020, Rheumatology Science and Practice.

COMPARATIVE EVALUATION OF THE LONG-TERM EFFICACY AND SAFETY OF THE INFLIXIMAB BIOSIMILAR BCD-055 AND REFERENCE INFLIXIMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS: RESULTS OF THE INTERNATIONAL MULTICENTER RANDOMIZED DOUBLE-BLIND PHASE III CLINICAL STUDY ASART-2

V. Mazurov, A. Lila, I. Gordeev, 2018, Rheumatology Science and Practice.

Long-term efficacy and safety of netakimab in the treatment of ankylosing spondylitis: results of Phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA

S. Lapshina, I. Gordeev, T. Dubinina, 2020, Modern Rheumatology Journal.